Cytodyn Inc (CYDY)

[BlackDoggie]

What you are misstating or misunderstanding is due to an apparent conflation of the one-week efficacy portion of the trial, and the 24-week open label extension.

According to today's PR, 33 patients have finished one-week efficacy at this point. However, this data is still blinded as far as we know. The company has given no indication that they have efficacy data at one week, much less what that data might say.

Also from today's PR, we know for sure that 11 patients have finished the 24-week open label extension, and the company is claiming zero detectable viral load for those patients at 25 weeks (total - 1 week for the trial vs. placebo, and 24 more for open label extension). They have access to this data because it is an open label arm of the trial. We do not know for sure that only 11 patients have finished the complete 25-week trial, although based on information provided in Jan/Feb, we can deduce that they can't have many (if any) more patients completed at this time. That data appears to be extremely good at this point, but it is a secondary endpoint, and unrelated to the one-week double blind arm of the trial which is providing the primary endpoint data.

All clear?